Psychedelics for Therapy 101: What Canadians Need to Know

Psychedelic therapy (also called psychedelic assisted therapy, PAT, or psychedelic integration) pairs a psychedelic experience with structured talk therapy. In clinical trials, researchers have reported encouraging results for conditions like PTSD and depression, and regulators consider the evidence incomplete. No psychedelic has been authorized as a treatment in Canada, and the substances involved remain controlled drugs.

This guide covers the legal status of psychedelic therapy in Canada, where the research stands, how clinical trials are structured, the risks, and the one related service that is fully legal today: integration therapy with a licensed therapist.

Is psychedelic therapy legal in Canada?

For almost everyone, no. Psilocybin, MDMA, LSD, and most other psychedelics are controlled substances under the Controlled Drugs and Substances Act, and Health Canada has not authorized any of them for sale as a treatment. Their safety and effectiveness are still under investigation. The only lawful settings where these substances can be administered are federally authorized clinical trials and other narrow, practitioner-initiated pathways under close Health Canada oversight.

There is one exception. Ketamine is an approved anaesthetic in Canada, and physicians can legally prescribe it off-label. A number of clinics across Canada offer ketamine treatment under medical supervision. Whether off-label ketamine is appropriate for a given patient is a decision made by a physician, and treatment is rarely covered by extended health benefits.

Everything else operates outside the law. An underground market of practitioners and self-described "healers," "guides," and "shamans" offers psychedelic sessions in Canada illegally. These services carry serious risks, covered below.

Practitioners interested in this field can read our guide to becoming a psychedelic therapist in Canada.

What conditions are researchers studying?

Clinical research on psychedelic assisted therapy has focused mainly on depression, particularly treatment-resistant depression, and post-traumatic stress disorder. Trials in these areas have reported reductions in symptoms among participants, alongside consistent limitations: small samples, difficulty blinding participants, and short follow-up periods. Research into other conditions, including anxiety, OCD, and substance use disorders, is at an earlier stage.

Regulators in Canada and the United States have reviewed parts of this evidence and judged it incomplete. In 2024, the U.S. FDA declined to approve MDMA-assisted therapy for PTSD and requested further study. Health Canada has not approved any psychedelic for any condition. Larger trials are underway.

How is psychedelic therapy structured in clinical trials?

Set and setting

Researchers in psychedelics and adjacent fields have used the term "set and setting" since at least 1961. In trials, both are carefully controlled.

Set refers to mindset: the emotions, attitudes, and expectations a participant brings to the session. An anxious or fearful participant may find those feelings magnified under the influence of psychedelics, which is one reason trials invest heavily in preparation and trust-building before any dosing session.

Setting refers to physical surroundings. Under the influence of psychedelics, judgment and perception are altered, so trial settings prioritize physical safety, comfort, quiet, and privacy. A typical trial room includes a couch or bed, eye shades, and music, with trained facilitators present throughout.

The four stages

While protocols vary, trials generally structure psychedelic assisted therapy in four stages:

1. Screening and education. Researchers assess whether a participant is eligible, review their medical and psychiatric history, and explain the potential benefits and risks of taking part. Screening excludes people with certain conditions and medications, including some heart conditions and a personal or family history of psychosis.
2. Preparation. The participant attends sessions with the study's therapists to set expectations, discuss what they hope to explore, and build trust with the team who will be present during dosing.
3. The dosing session. The participant receives the substance in a controlled setting, monitored at all times by trained facilitators, usually two, for a session that can last several hours.
4. Integration. In follow-up sessions, the participant works with a therapist to process and contextualize the experience. Researchers consider integration central to any therapeutic effect, which is why psychedelic assisted therapy is sometimes called "integration therapy."

What are the dangers of psychedelic therapy?

Legal risks

Possessing or transporting controlled substances is illegal in Canada. Anyone buying or holding psychedelics outside a clinical trial can be charged, regardless of their intended use.

Physical health risks

Psychedelics are powerful drugs with real physiological effects. MDMA raises heart rate, blood pressure, and body temperature, and has caused serious harm and deaths in uncontrolled settings, particularly with high doses, warm environments, or underlying heart conditions. Combining some psychedelics with antidepressants can cause serotonin syndrome, a potentially fatal condition. Clinical trials manage these risks by screening out vulnerable participants and monitoring vital signs; none of those safeguards exist outside a trial. If you have an ongoing health condition or take any medication, including SSRIs, talk to a physician before going anywhere near these substances.

Contaminated and unregulated supply

Substances sold illegally come with no oversight of manufacturing, dosage, or purity. Powdered and pill-form drugs may be diluted with unknown additives or contaminated with fentanyl or carfentanil, where even trace amounts can be deadly. Liquid or blotter products sold as LSD sometimes contain little-documented research chemicals instead. There is no reliable way for a buyer to know what they are taking.

Psychosis and mania

In rare cases, psychedelics can trigger psychotic or manic states, even in clinical settings at controlled doses. People with a personal or family history of psychosis or mania are at higher risk, which is why trials screen for it. Researchers have not identified the mechanisms behind these reactions.

Hallucinogen-persisting perception disorder (HPPD)

Rarely, people who take psychedelics experience hallucinogen-persisting perception disorder: visual effects that continue after the experience has ended and may last days, months, or years, sometimes returning during periods of stress. HPPD is a recognized DSM-5 diagnosis, and its mechanisms are not well understood. It is not limited to psychedelics; some people develop HPPD after cannabis or SSRIs, and some without any substance use at all.

Exploitation and abuse

Psychedelics make people vulnerable in ways ordinary therapy does not. Under their influence, judgment, perception, and inhibitions are altered, and an unethical practitioner can take advantage of that vulnerability. Documented harms include sexual abuse, financial exploitation, and manipulation of a person's beliefs and behaviours. Harm can also happen without intent, as when a practitioner introduces touch or frames the experience through their own spiritual beliefs in ways that override the client's boundaries.

This risk is highest in the underground market, where practitioners answer to no regulatory college, no ethics board, and no code of ethics. A licensed therapist can lose their license; an underground guide has nothing to lose.

Integration therapy: legal support after a psychedelic experience

One part of this field is fully legal in Canada today: integration therapy. Talk therapy that helps someone process a psychedelic experience they have already had involves no controlled substances, and licensed therapists can provide it like any other form of counselling.

People seek integration support for different reasons. Some have taken a psychedelic recreationally and had an experience so powerful, positive or negative, that it challenged their normal perspective. Others are struggling with the aftermath of a difficult experience and feeling anxious or uncertain about their own mental health.

Integration-only therapy differs from the integration stage of a supervised session in a few ways:

• Recounting the experience. The therapist was not present, so it is up to the client to provide details as they remember them.
• Addressing perspective shifts after the fact. The client may have spent weeks or months trying to make sense of major changes in perspective without help. The therapist's job is to help clarify those changes and integrate them into daily life.
• Working through anxiety and distress. A difficult experience can leave lasting fear or confusion. A trained therapist provides non-judgmental support in processing it.

If you or someone you know is struggling after a psychedelic experience, a licensed therapist can help, and seeking that help does not expose you to legal risk.

Summary

• Psychedelics like psilocybin and MDMA are controlled substances in Canada, and Health Canada has not authorized any of them as a treatment. The only lawful access is through clinical trials and other narrow, federally controlled pathways.
• Ketamine is the exception in legal status: it is an approved anaesthetic that physicians can prescribe off-label, a decision made between a doctor and their patient.
• Clinical trials pair psychedelics with structured screening, preparation, and integration therapy, and researchers consider the therapy component central to any benefit.
• The underground market carries serious risks: criminal liability, contaminated and unregulated substances, and practitioners who answer to no ethical oversight.
• Integration therapy, talk therapy that helps someone process an experience they have already had, is legal and available from licensed therapists across Canada.
• Anyone seeking help for depression, trauma, or other mental health challenges can work with a licensed therapist using established, legal approaches.